Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient

Bipolar Disorders

Volumn 8, Issue 4, 2006, Pages 415-417

  Saraga, Michael ^a   Preisig, Martin ^a   Zullino, Daniele Fabio ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Antiviral agents; Glucuronidation; Interaction; Protein binding; Valproate

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE; DIDANOSINE; EFAVIRENZ; GLUCURONOSYLTRANSFERASE; LAMIVUDINE; METHADONE; PLASMA PROTEIN; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG ELIMINATION; ENZYME INDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MENTAL PATIENT; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTICONVULSANTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; OXAZINES; SUBSTANCE-RELATED DISORDERS; VALPROIC ACID;

EID: 33746162357     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2006.00331.x     Document Type: Article

References (6)

1. Otto-Salaj LL, Stevenson LY. Influence of psychiatric diagnoses and symptoms on HIV risk behavior in adults with serious mental illness. AIDS Read 2001; 11: 197-198.
2. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC. Antiretrovirals, part II: Focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 2004; 45: 524-535.
3. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004; 32: 140-148.
4. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
5. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121.
6. Boffito M, Back DJ, Blaschke TF et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-835.